(VRTX) Vertex Pharmaceuticals - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US92532F1003
VRTX EPS (Earnings per Share)
VRTX Revenue
VRTX: Cystic Fibrosis, Pain Management, Sickle Cell, Beta Thalassemia, Kidney Disease
Vertex Pharmaceuticals Incorporated is a biotechnology company that has established itself as a leader in the development and commercialization of therapies for cystic fibrosis (CF), a life-threatening genetic disorder. The companys robust portfolio includes several approved treatments, such as TRIKAFTA/KAFTRIO, ALYFTREK, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations and age groups, providing a comprehensive approach to managing CF.
Beyond its CF franchise, Vertex is making significant strides in expanding its pipeline to address other serious diseases, including sickle cell disease, transfusion-dependent beta thalassemia, acute pain, APOL1-mediated kidney disease, Type 1 Diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. The companys research and development efforts are supported by collaborations with prominent biotech companies like CRISPR Therapeutics AG, Moderna, Inc., and Entrada Therapeutics, Inc.
From a technical analysis perspective, Vertexs stock (VRTX) is currently trading at $442.05, slightly below its SMA20 at $443.99, but significantly below its SMA50 and SMA200, indicating a potential short-term correction. The Average True Range (ATR) of 13.25 (3.00%) suggests moderate volatility. Given the 52-week high and low range ($516.74 - $396.64), the stock is trading near the middle of this range.
Fundamentally, Vertex boasts a substantial market capitalization of $113.517 billion, underscoring its size and influence in the biotechnology sector. The forward P/E ratio of 24.75 indicates that investors are willing to pay a premium for the companys expected earnings growth, likely driven by its strong pipeline and existing commercial successes.
Forecasting future performance, we can anticipate that Vertex will continue to drive growth through its CF therapies, while its expanding pipeline addresses significant unmet medical needs. Assuming successful clinical trials and regulatory approvals for its pipeline assets, Vertex could experience significant upside. Technically, a breakout above the SMA50 and SMA200 could signal a bullish trend, potentially driving the stock towards its 52-week high. Conversely, failure to progress pipeline assets or a decline in CF treatment sales could negatively impact the stock. As such, a potential forecast is that VRTX could reach $500 in the next 6-12 months if it continues to execute on its pipeline and maintains its commercial momentum.
Additional Sources for VRTX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
VRTX Stock Overview
Market Cap in USD | 116,958m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Biotechnology |
IPO / Inception | 1991-07-24 |
VRTX Stock Ratings
Growth Rating | 40.2 |
Fundamental | 7.94 |
Dividend Rating | 0.0 |
Rel. Strength | 2.8 |
Analysts | 3.85 of 5 |
Fair Price Momentum | 384.47 USD |
Fair Price DCF | - |
VRTX Dividends
Currently no dividends paidVRTX Growth Ratios
Growth Correlation 3m | -68.7% |
Growth Correlation 12m | -19.9% |
Growth Correlation 5y | 89.9% |
CAGR 5y | 8.55% |
CAGR/Max DD 5y | 0.21 |
Sharpe Ratio 12m | 1.53 |
Alpha | -15.55 |
Beta | 0.727 |
Volatility | 22.64% |
Current Volume | 1363.3k |
Average Volume 20d | 1248.2k |
As of June 19, 2025, the stock is trading at USD 441.99 with a total of 1,363,329 shares traded.
Over the past week, the price has changed by -2.11%, over one month by +0.30%, over three months by -13.97% and over the past year by -6.69%.
Neither. Based on ValueRay´s Fundamental Analyses, Vertex Pharmaceuticals is currently (June 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 7.94 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of VRTX is around 384.47 USD . This means that VRTX is currently overvalued and has a potential downside of -13.01%.
Vertex Pharmaceuticals has received a consensus analysts rating of 3.85. Therefor, it is recommend to buy VRTX.
- Strong Buy: 14
- Buy: 4
- Hold: 14
- Sell: 1
- Strong Sell: 1
According to our own proprietary Forecast Model, VRTX Vertex Pharmaceuticals will be worth about 434.3 in June 2026. The stock is currently trading at 441.99. This means that the stock has a potential downside of -1.75%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 500.1 | 13.2% |
Analysts Target Price | 500.3 | 13.2% |
ValueRay Target Price | 434.3 | -1.7% |